Incidence of high chromogranin A serum levels in patients with non metastatic prostate adenocarcinoma

Journal of Experimental and Clinical Cancer Research

Volumn 29, Issue 1, 2010, Pages

  Appetecchia, Marialuisa ^a   Meçule, Aurela ^a   Pasimeni, Giuseppe ^a   Iannucci, Concetta V ^a   De Carli, Piero ^a   Baldelli, Roberto ^a   Barnabei, Agnese ^a   Cigliana, Giovanni ^a   Sperduti, Isabella ^a   Gallucci, Michele ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN A; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PATIENT; DISEASE SEVERITY; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; TISSUE DIFFERENTIATION; ADENOCARCINOMA; BLOOD; CANCER STAGING; INCIDENCE; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; RETROSPECTIVE STUDY;

ADENOCARCINOMA; ADULT; AGED; CHROMOGRANIN A; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 78650149925     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-29-166     Document Type: Article

References (31)

1. Neuroendocrine serum tumour markers in hormone-resistant prostate cancer. T Hvamstad A Jordal N Hekmat, et al. Eur Urol 2003 44 215 21 10.1016/S0302-2838(03)00257-4 12875941
2. Secondary hormonal manipulation. DC Smith NA Dawson DL Trump, Genitourinary oncology Philadelphia Lippincott Williams & Wilkins 2 2000 855 76
3. Neuroendocrine cells in benign and malignant prostate tissue: morphogenesis, proliferation, and androgen receptor status. H Bonkhoff, Prostate 1998 8 18 22, 10.1002/(SICI)1097-0045(1998)8+<18::AID-PROS4>3.0.CO;2-C
4. Neuroendocrine pathogenesis in adenocarcinoma of the prostate. J Hansson PA Abrahamsson, Ann Oncol 2001 12 145 S152 10.1023/A:1012407027175 11300315
5. Presence of receptors for bombesin/gastrin releasing peptide and mRNA for three receptors subtypes in human prostate cancer. B Sun G Halmos AV Schally, et al. Prostate 2000 42 295 303 10.1002/(SICI)1097-0045(20000301)42:4<295:: AID-PROS7>3.0.CO;2-B 10679759
6. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone refractory disease. A Berruti A Mosca M Tucci, et al. Endocr Relat Cancer 2005 12 109 17 10.1677/erc.1.00876 15788643
7. Elevated plasma chromogranin A concentrations in prostatic carcinoma. D Kadmon TC Thomson GR Lynch, et al. J Urol 1991 146 358 361 1856931
8. Elevated levels of serum secretoneurin in patients with therapy resistant carcinoma of prostate. R Ischia A Hobisch R Bauer, et al. J Urol 2000 163 1161 1165 10.1016/S0022-5347(05)67714-2 10737487
9. Serum chromogranin A in advanced prostate cancer. M Ferrero-Pous AM Hersant A Pecking, et al. Br J Urol Int 2001 88 790 6
10. Clinical understaging in patients with prostate adenocarcinoma submitted to radical prostatectomy: predictive value of serum Chromogranin A. A Sciarpa G Voria S Monti, et al. Prostate 2004 58 421 428 10.1002/pros.10347 14968443
11. Neuroendocrine differentiation is not prognostic of failure after radical prostatectomy but correlates with tumor volume. G Ahlegren K Pedersen S Lundberg, et al. Urology 2000 56 1011 1015 10.1016/S0090-4295(00)00838-4 11113749
12. TNM classification of malignant tumors., Sobin LH, Wittekind Ch, 6 2002 - - Either ISSN or Journal title must be supplied.
13. Histologic grade, clinical stage, and patient age in prostate cancer. DF Gleason, NCI Monogr 1988 15 8 3173500
14. Serum chromogranin-A in advanced prostate cancer. M Ferrero-Poüs AM Hersant A Pecking, et al. BJU Int 2001 88 790 6 11890255
15. Neuroendocrine differentiation in prostate adenocarcinoma. A Sciarra, Eur Urol 2007 52 1373 17985422
16. Neuroendocrine differentiation in carcinomas of prostate: do neuroendocrine serum markers reflect immunohistochemical findings? A Angelsen U Syversen OA Haugen, et al. Prostate 1997 30 1 6 10.1002/(SICI)1097- 0045(19970101)30:1<1::AID-PROS1>3.0.CO;2-T 9018329
17. Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin. N Xing J Qian D Bostwick, et al. Prostate 2001 48 7 15 10.1002/pros.1076 11391682
18. Frequency and number of neuroendocrine tumor cells in prostate cancer: no difference between radical prostatectomy specimens from patients with and without neoadjuvant hormonal therapy. S Shimizu J Kumagai Y Eishi, et al. Prostate 2007 67 645 52 10.1002/pros.20493 17342745
19. Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma. T Fixemer K Remberger H Bonkhoff, Prostate 2002 53 118 23 10.1002/pros.10133 12242726
20. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. IF Tannock D Osoba MR Stockler, et al. J Clin Oncol 1996 14 1756 64 8656243
21. Plasma neuroendocrine markers in patients with benign prostatic hypertrophy and prostate carcinoma. O Cussenot JM Villette A Valeri, et al. J Urol 1996 155 1340 1343 10.1016/S0022-5347(01)66261-X 8632569
22. Regressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatment. G Ahlegren K Pedersen S Lundberg, et al. Prostate 2000 42 274 279 10.1002/(SICI)1097-0045(20000301)42:4<274::AID- PROS4>3.0.CO;2-R 10679756
23. Neuroendocrine serum tumour markers in hormone-resistant prostate cancer. T Hvamstad A Jordal N Hekmat, et al. Eur Urol 2003 44 215 221 10.1016/S0302-2838(03)00257-4 12875941
24. Somatostatin receptors: from basic science to clinical approach. Unlabeled somatostatin analogues-1: prostate cancer. A Mosca L Dogliotti A Berruti, et al. Dig Liver Dis 2004 36 60 S67 10.1016/j.dld.2003.11.021
25. Chromogranin A concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer. S Isshiki K Akakura A Komiya, et al. J Urol 2002 167 512 515 10.1016/S0022-5347(01)69075-X 11792908
26. The chromogranin-A (CgA) in prostate cancer. S Ranno M Motta E Rampello, et al. Arch Gerontol Geriatr 2006 43 117 26 10.1016/j.archger.2005.09.008 16280180
27. Plasma chromogranin A in prostatic carcinoma and neuroendocrine tumors. N Kimura S Hoshi M Takahashi, et al. J Urol 1997 157 565 7 10.1016/S0022-5347(01) 65203-0 8996358
28. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. D Hirano Y Okada S Minei, et al. Eur Urol 2004 45 586 592 10.1016/j.eururo.2003.11.032 15082200
29. The possible role of chromogranin A as a prognostic factor in organ-confined prostate cancer. F Grimaldi C Valotto G Barbina, et al. Int J Biol Markers 2006 21 229 34 17177161
30. Characterization of neuroendocrine differentiation in human benign prostate and prostate adenocarcinoma. AG Aprikian C Cordon-Cardo W Fair, et al. Cancer 1993 71 3952 65 10.1002/1097-0142(19930615)71:12<3952::AID- CNCR2820711226>3.0.CO;2-X 7685237
31. Chromogranin A and B secretogranin II in prostatic adenocarcinomas: neuroendocrine expression in patients untreated and treated with androgen deprivation therapy. G Pruneti S Galli RS Rossi, et al. Prostate 1998 34 113 20 10.1002/(SICI)1097-0045(19980201)34:2<113::AID-PROS5>3.0.CO;2-L 9465942